Boston-based Third Rock Ventures today launched the genomic search engine start-up, Warp Drive Bio, as part of a partnership with the French pharmaceutical company Sanofi. Sanofi is investing $125 million into the company, which Third Rock — an venture firm as well as incubator — has been developing for the last two years. PRESS RELEASE: [...]
You are browsing the archive for Sanofi - peHUB.
At Long Last!: Sanofi-Genzyme could finally be happening
Growing: PepsiCo buys most of Russian dairy & juice company Wimm-Bill-Dann, plans full acquisition
Dealing: Nelson Peltz might be orchestrating another deal for Wendy’s/Arby’s, instead of just splitting them up
What’s in a Name?: Groupon is reportedly trying to buy Hipster
Sanofi-Aventis has agreed to acquire Fovea Pharmaceuticals SA, a Paris, France-based drug company focused on ophthalmic diseases. The deal is valued at up to €370 million, including an upfront payment and possible milestone payments. Fovea had raised over $60 million in VC funding from firms like Forbion Capital Partners, Sofinnova Partners, Abingworth, GIMV, The Wellcome Trust and CAPE.
Sanofi-aventis (NYSE: SNY) has agreed to acquire BiPar Sciences Inc., a Brisbane, Calif.-based developer of PARP inhibitors as cancer therapies. The deal could be worth up to $500 million, based on the achievement of milestones for BiPar’s lead candidate. BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.